Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sun Pharma | BSE | Healthcare | Pharmaceuticals | ₹4.16T | 36.3x | 1.28 | ₹1,732.70 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20% Upside | Upgrade to Pro+ | |
Sun Pharma | NSE | Healthcare | Pharmaceuticals | ₹4.15T | 36.3x | 1.28 | ₹1,729.50 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20% Upside | Upgrade to Pro+ | |
Divi's Labs | BSE | Healthcare | Pharmaceuticals | ₹1.58T | 76.5x | 1.6 | ₹5,936.35 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.7% Downside | Upgrade to Pro+ | |
Divi's Labs | NSE | Healthcare | Pharmaceuticals | ₹1.57T | 76.5x | 1.6 | ₹5,935.90 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.7% Downside | Upgrade to Pro+ | |
Cipla | BSE | Healthcare | Pharmaceuticals | ₹1.18T | 23.5x | 0.69 | ₹1,453.50 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.1% Upside | Upgrade to Pro+ | |
Cipla | NSE | Healthcare | Pharmaceuticals | ₹1.17T | 23.5x | 0.69 | ₹1,454.30 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.1% Upside | Upgrade to Pro+ | |
Max Healthcare Institute | BSE | Healthcare | Healthcare Providers & Services | ₹1.11T | 103x | -22.14 | ₹1,068.10 | -6.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.7% Upside | Upgrade to Pro+ | |
Max Healthcare Institute | NSE | Healthcare | Healthcare Providers & Services | ₹1.11T | 103x | -22.14 | ₹1,070.10 | -6.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.8% Upside | Upgrade to Pro+ | |
Torrent Pharma | BSE | Healthcare | Pharmaceuticals | ₹1.08T | 57.9x | 2.41 | ₹3,186 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.9% Upside | Upgrade to Pro+ | |
Torrent Pharma | NSE | Healthcare | Pharmaceuticals | ₹1.08T | 57.9x | 2.41 | ₹3,194.35 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.9% Upside | Upgrade to Pro+ | |
Mankind Pharma | BSE | Healthcare | Pharmaceuticals | ₹1.04T | 48.3x | 2.83 | ₹2,478.95 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.8% Upside | Upgrade to Pro+ | |
Mankind Pharma | NSE | Healthcare | Pharmaceuticals | ₹1.04T | 48.3x | 2.83 | ₹2,478.45 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.8% Upside | Upgrade to Pro+ | |
Dr Reddy’s Laboratories | BSE | Healthcare | Pharmaceuticals | ₹1.02T | 18.9x | 7.2 | ₹1,222.30 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.6% Upside | Upgrade to Pro+ | |
Dr Reddy’s Laboratories | NSE | Healthcare | Pharmaceuticals | ₹1.02T | 18.9x | 7.2 | ₹1,221.70 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.6% Upside | Upgrade to Pro+ | |
Lupin | NSE | Healthcare | Pharmaceuticals | ₹984.88B | 37.3x | 0.39 | ₹2,162.15 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.2% Upside | Upgrade to Pro+ | |
Lupin | BSE | Healthcare | Pharmaceuticals | ₹982.71B | 37.3x | 0.39 | ₹2,157.55 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.4% Upside | Upgrade to Pro+ | |
Zydus Lifesciences | BSE | Healthcare | Pharmaceuticals | ₹968.45B | 21.3x | 0.41 | ₹961.70 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.6% Upside | Upgrade to Pro+ | |
Zydus Lifesciences | NSE | Healthcare | Pharmaceuticals | ₹968.20B | 21.3x | 0.41 | ₹963.20 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.6% Upside | Upgrade to Pro+ | |
Apollo Hospitals | BSE | Healthcare | Healthcare Providers & Services | ₹964.36B | 80.4x | 1.15 | ₹6,701.05 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.2% Upside | Upgrade to Pro+ | |
Apollo Hospitals | NSE | Healthcare | Healthcare Providers & Services | ₹963.33B | 80.4x | 1.15 | ₹6,704 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.1% Upside | Upgrade to Pro+ | |
Aurobindo Pharma | BSE | Healthcare | Pharmaceuticals | ₹682.18B | 19.6x | 0.74 | ₹1,175.90 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.1% Upside | Upgrade to Pro+ | |
Aurobindo Pharma | NSE | Healthcare | Pharmaceuticals | ₹679.77B | 19.6x | 0.74 | ₹1,169.95 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32% Upside | Upgrade to Pro+ | |
Abbott India | NSE | Healthcare | Pharmaceuticals | ₹627.87B | 47x | 2.88 | ₹29,555 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9% Upside | Upgrade to Pro+ | |
Abbott India | BSE | Healthcare | Pharmaceuticals | ₹627.42B | 47x | 2.88 | ₹29,547.85 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9% Upside | Upgrade to Pro+ | |
Alkem Laboratories Ltd BO | BSE | Healthcare | Pharmaceuticals | ₹576.69B | 26.7x | 0.78 | ₹4,812 | -6.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.3% Upside | Upgrade to Pro+ | |
Alkem Laboratories Ltd | NSE | Healthcare | Pharmaceuticals | ₹575.57B | 26.7x | 0.78 | ₹4,805.50 | -6.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.4% Upside | Upgrade to Pro+ | |
Fortis Healthcare | BSE | Healthcare | Healthcare Providers & Services | ₹473.32B | 61.6x | 3.76 | ₹627.55 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.1% Upside | Upgrade to Pro+ | |
Fortis Healthcare | NSE | Healthcare | Healthcare Providers & Services | ₹472.91B | 61.6x | 3.76 | ₹627.40 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.1% Upside | Upgrade to Pro+ | |
Biocon | BSE | Healthcare | Biotechnology & Medical Research | ₹448.98B | 55.9x | -1.74 | ₹375.20 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.5% Upside | Upgrade to Pro+ | |
Biocon | NSE | Healthcare | Biotechnology & Medical Research | ₹448.92B | 55.9x | -1.74 | ₹375.40 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.4% Upside | Upgrade to Pro+ | |
Glenmark Pharma | NSE | Healthcare | Pharmaceuticals | ₹428.31B | -49.1x | 0.05 | ₹1,517.75 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.5% Upside | Upgrade to Pro+ | |
Glenmark Pharma | BSE | Healthcare | Pharmaceuticals | ₹427.75B | -49.1x | 0.05 | ₹1,516.95 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.5% Upside | Upgrade to Pro+ | |
Ipca Laboratories | BSE | Healthcare | Pharmaceuticals | ₹366.86B | 55.6x | 1.69 | ₹1,446.80 | -3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.6% Upside | Upgrade to Pro+ | |
Ipca Laboratories | NSE | Healthcare | Pharmaceuticals | ₹366.29B | 55.6x | 1.69 | ₹1,445.75 | -4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.6% Upside | Upgrade to Pro+ | |
GlaxoSmithkline Pharma | NSE | Healthcare | Pharmaceuticals | ₹362.68B | 53.6x | 8.9 | ₹2,146.65 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.6% Upside | Upgrade to Pro+ | |
GlaxoSmithkline Pharma | BSE | Healthcare | Pharmaceuticals | ₹362.16B | 53.6x | 8.9 | ₹2,133.35 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.9% Upside | Upgrade to Pro+ | |
Laurus Labs | BSE | Healthcare | Pharmaceuticals | ₹335.87B | 168.1x | 26.1 | ₹622.80 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -21.3% Downside | Upgrade to Pro+ | |
Laurus Labs | NSE | Healthcare | Pharmaceuticals | ₹335.15B | 168.1x | 26.1 | ₹622.20 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -21.3% Downside | Upgrade to Pro+ | |
Ajanta Pharma Ltd | NSE | Healthcare | Pharmaceuticals | ₹324.23B | 36.3x | 1.62 | ₹2,597 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20% Upside | Upgrade to Pro+ | |
Ajanta Pharma Ltd-BO | BSE | Healthcare | Pharmaceuticals | ₹323.61B | 36.3x | 1.62 | ₹2,593.65 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.1% Upside | Upgrade to Pro+ | |
Global Health | BSE | Healthcare | Healthcare Providers & Services | ₹313.92B | 61.1x | 5.07 | ₹1,131.15 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.5% Upside | Upgrade to Pro+ | |
Global Health | NSE | Healthcare | Healthcare Providers & Services | ₹313.92B | 61.1x | 5.07 | ₹1,127.80 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.4% Upside | Upgrade to Pro+ | |
Piramal Pharma | BSE | Healthcare | Pharmaceuticals | ₹300.23B | 784.4x | 3.73 | ₹220.25 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.8% Upside | Upgrade to Pro+ | |
Piramal Pharma | NSE | Healthcare | Pharmaceuticals | ₹300.23B | 784.4x | 3.73 | ₹220.01 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.9% Upside | Upgrade to Pro+ | |
Suven Pharma | BSE | Healthcare | Pharmaceuticals | ₹294.70B | 111.3x | -2.77 | ₹1,115.95 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.2% Upside | Upgrade to Pro+ | |
Suven Pharma | NSE | Healthcare | Pharmaceuticals | ₹294.70B | 111.3x | -2.77 | ₹1,118.95 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24% Upside | Upgrade to Pro+ | |
Syngene International Ltd BO | BSE | Healthcare | Biotechnology & Medical Research | ₹294.06B | 58.4x | ₹730.45 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.4% Upside | Upgrade to Pro+ | ||
Syngene International Ltd | NSE | Healthcare | Biotechnology & Medical Research | ₹293.13B | 58.4x | ₹730.90 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.5% Upside | Upgrade to Pro+ | ||
Narayana Hrudayalaya | NSE | Healthcare | Healthcare Providers & Services | ₹283.67B | 36.4x | 6.5 | ₹1,395.85 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.2% Upside | Upgrade to Pro+ | |
Narayana Hrudayalaya | BSE | Healthcare | Healthcare Providers & Services | ₹283.41B | 36.4x | 6.5 | ₹1,397.95 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.2% Upside | Upgrade to Pro+ |